GLPwatch
Mounjaro for Obesity
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for obesity, and any use for this condition is off-label or investigational. A meta-analysis of direct comparative studies found tirzepatide linked to weight loss in type 2 diabetes patients.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Obesity |
| Approval status | Investigational / off-label |
| Research papers | 50 |
Mounjaro is not FDA-approved for obesity; the research below reflects investigational or off-label study only.
Research on tirzepatide for obesity (50)
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
- Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
- GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
- Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
- Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.
- Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
- Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
- The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
- Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.
- Tirzepatide: First Approval.
- The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
- Structural determinants of dual incretin receptor agonism by tirzepatide.
- Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
- Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
- The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.